CN116098913A - 车叶草苷在成骨细胞系mc3t3-e1增殖与分化的应用 - Google Patents
车叶草苷在成骨细胞系mc3t3-e1增殖与分化的应用 Download PDFInfo
- Publication number
- CN116098913A CN116098913A CN202310243299.2A CN202310243299A CN116098913A CN 116098913 A CN116098913 A CN 116098913A CN 202310243299 A CN202310243299 A CN 202310243299A CN 116098913 A CN116098913 A CN 116098913A
- Authority
- CN
- China
- Prior art keywords
- asperuloside
- proliferation
- differentiation
- mc3t3
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IBIPGYWNOBGEMH-DILZHRMZSA-N asperuloside Chemical compound O([C@@H]1OC=C2C(=O)O[C@H]3C=C([C@@H]1[C@H]32)COC(=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBIPGYWNOBGEMH-DILZHRMZSA-N 0.000 title claims abstract description 37
- COUXBBBIXWWAEP-AGUBZPQCSA-N asperuloside Natural products CC(=O)OCC1=C[C@@H]2OC(=O)C3=CO[C@@H](OC[C@H]4O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]4O)[C@H]1[C@H]23 COUXBBBIXWWAEP-AGUBZPQCSA-N 0.000 title claims abstract description 37
- 210000000963 osteoblast Anatomy 0.000 title claims abstract description 14
- 230000035755 proliferation Effects 0.000 title claims abstract description 12
- 230000004069 differentiation Effects 0.000 title claims abstract description 10
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 20
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 102000014128 RANK Ligand Human genes 0.000 abstract description 14
- 108010025832 RANK Ligand Proteins 0.000 abstract description 14
- 230000011164 ossification Effects 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 230000004663 cell proliferation Effects 0.000 abstract description 5
- 230000018678 bone mineralization Effects 0.000 abstract description 3
- 238000012404 In vitro experiment Methods 0.000 abstract description 2
- 230000024245 cell differentiation Effects 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 34
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 16
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 16
- 102000008108 Osteoprotegerin Human genes 0.000 description 14
- 108010035042 Osteoprotegerin Proteins 0.000 description 14
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 14
- 238000004113 cell culture Methods 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000033558 biomineral tissue development Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- AVPCPPOOQICIRJ-UHFFFAOYSA-L sodium glycerol 2-phosphate Chemical compound [Na+].[Na+].OCC(CO)OP([O-])([O-])=O AVPCPPOOQICIRJ-UHFFFAOYSA-L 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 159000000007 calcium salts Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 230000002177 osteoclastogenic effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003651 pro-proliferative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及车叶草苷的新用途,具体是车叶草苷在成骨细胞系MC3T3‑E1增殖与分化中的应用。本发明通过体外实验和分子生物学实验证明了车叶草苷可以促进MC3T3‑E1细胞增殖与分化,使ALP活性增高,上调OPG/RANKL的比值,促进骨的形成以及矿化结节的生成,探索并提供了车叶草苷促进成骨细胞增殖与分化的机制。本发明为车叶草苷在骨质疏松症的治疗与预防提供了理论依据。
Description
技术领域
本发明涉及车叶草苷的新用途,具体是车叶草苷在成骨细胞系MC3T3-E1增殖与分化中的应用。
背景技术
骨质疏松症(Osteoporosis,OP)是以骨质减少、骨组织细微结构破坏、骨脆性增加、骨折危险性增大为特征的全身性的慢性代谢性骨病,被世界卫生组织列为仅次于心血管系统疾病的第二大危害人类健康的疾病。根据国际骨质疏松基金会的数据显示,在全球范围内超过50岁的人群中有三分之一的女性和五分之一的男性会发生骨质疏松性骨折。鉴于许多国家人口老龄化正在迅速增加,骨质疏松症患者逐渐增多,骨质疏松症己成为全球范围内广泛存在的严重社会公众健康问题。因此,如何预防以及治疗质疏松症将成为一项重要课题。
骨质疏松症的主要原因是骨形成和骨吸收失衡。成骨细胞是骨形成的主要功能细胞,负责骨基质的合成、分泌和矿化。骨组织不断地进行着重建,骨重建过程包括成骨细胞形成新骨和破骨细胞吸收旧骨。正常情况下成骨细胞和破骨细胞所介导的骨形成和骨吸收处于平衡状态,在病理条件下平衡打破即可引起骨代谢异常而引发相关疾病,如骨质疏松症。因此,破骨与成骨过程的平衡是维持正常骨量的关键。目前,骨质疏松症治疗药物主要分为两类:抑制骨吸收和促进骨形成,其中甲状旁腺激素是美国食品药品监督管理局唯一批准的促进骨形成的药物,但是甲状旁腺激素可以引发骨肉瘤,导致其在临床上大规模应用受到限制。
车叶草苷(Asperuloside,Asp)是一种环烯醚萜类化合物,目前,国内外的研究发现,车叶草苷具有抗炎、镇痛、降血压、抗肿瘤等广泛天然药理作用。车叶草苷作为一种已经有的物质,尽管有确切的分子式和结构式,但其研究的活性不高,作为单体在促进成骨细胞增殖、治疗骨质疏松症中的应用还未见报道。
发明内容
本发明的目的在于提供车叶草苷在成骨细胞系MC3T3-E1增殖与分化药物中的应用。
为实现上述发明目的,本发明采用以下技术方案:
本发明提供了车叶草苷在制备成骨细胞系MC3T3-E1增殖与分化药物中的应用。
车叶草苷的结构式如下:
上述技术方案中,进一步地,所述药物为治疗或预防骨质疏松的药物。
本发明还提供了车叶草苷在制备预防骨质疏松保健食品中的应用。
上述技术方案中,进一步地,所述车叶草苷的浓度为5~20μM;优选地,所述车叶草苷的浓度为10~20μM。
本发明提供了一种预防或治疗骨质疏松的药物,所述药物以车叶草苷为活性成分。
上述技术方案中,进一步地,所述药物以车叶草苷为唯一活性成分。
上述技术方案中,进一步地,所述药物为口服制剂或注射制剂。
本发明提供了一种预防骨质疏松的保健食品,所述保健食品包含车叶草苷。
本申请采用的实验验证方法如下:
(1)用浓度分别为5、10、20μM的车叶草苷处理MC3T3-E1细胞24、48、72h,并采用CCK-8试剂盒检测MC3T3-E1细胞活力、ALP试剂盒检测ALP活性;
(2)用浓度分别为5、10、20μM的车叶草苷处理MC3T3-E1细胞72h后,用real timePCR法检测细胞中OPG和RANKL mRNA表达水平;骨保护素(OPG)是由成骨细胞合成的一种参与骨重建的糖蛋白,其通过阻断RANK与RANKL之间的相互作用抑制破骨细胞的活性,阻碍骨吸收。所以,OPG/RANKL表达比值是骨量的主要决定因素,是评价骨形成的重要标志,并且在大多数骨溶解疾病的诊断治疗中有着重要的意义。
(3)用浓度分别为5、10、20μM的车叶草苷处理MC3T3-E1细胞72h后,继续用条件培养液培养17d,然后用Von Kossa染色法检测MC3T3-E1细胞产生矿化结节情况。
与现有技术相比,本发明的有益效果:
本发明通过体外实验和分子生物学实验证明了车叶草苷可以促进MC3T3-E1细胞增殖与分化,使ALP活性增高,上调OPG/RANKL的比值,促进骨的形成以及矿化结节的生成,探索并提供了车叶草苷促进成骨细胞增殖与分化的机制。本发明为车叶草苷在骨质疏松症的治疗与预防提供了理论依据。
附图说明
图1不同浓度Asp促进MC3T3-E1细胞增殖结果图;
图2不同浓度Asp对MC3T3-E1细胞中ALP活性的影响结果图;
图3不同浓度Asp对MC3T3-E1细胞中OPG/RANKL mRNA表达情况的影响结果图;
图4不同浓度Asp对MC3T3-E1的细胞矿化结节形成影响结果图。
具体实施方式
以下结合具体实施例对本发明作进一步说明,但不以任何方式限制本发明。
以下实施例中所用细胞、试剂、器材均可通过商业渠道购买得到。
实施例1
1、实验方案:
①细胞增殖能力的检测
MC3T3-E1细胞以1×105/ml个细胞接种于96孔细胞培养板中,每孔100μl细胞悬液。待细胞贴壁后,弃去原细胞培养液,加入不同浓度的Asp(5μM、10μM和20μM),每孔100μl。细胞继续在体积分数为5% CO2、37℃的细胞培养箱中继续培养24h、48h和72h,然后每孔加入10μl的CCK-8溶液,继续培养0.5h。用酶标仪测定450nm的OD值。
②碱性磷酸酶(ALP)活性检测
MC3T3-E1细胞以2×105/ml个细胞接种于24孔细胞培养板中,每孔300μl细胞悬液。待细胞贴壁后,弃去原细胞培养液,加入条件培养液(含有50μg/ml维生素C、10mMβ-甘油磷酸钠的DMEM细胞培养液),每孔300μl,在体积分数为5% CO2、37℃的细胞培养箱中继续培养7d,每天换液一次。然后弃去原细胞培养液,加入不同浓度的Asp(5μM、10μM和20μM)药液,每孔300μl。培养24h、48h和72h后,按照ALP试剂盒说明书测定ALP含量,BCA试剂盒测定蛋白总含量,并且按照ALP试剂盒说明中提供的公式计算ALP含量。
③Real-time PCR检测OPG/RANKL mRNA表达情况
将MC3T3-E1细胞接种于6孔细胞培养板中,每孔1ml细胞悬液。待细胞长到约有90%汇合度时,弃去原培养液,加入不同浓度的Asp(5μM、10μM和20μM)药液,每孔各1ml。培养72h后,提取总RNA,检测OPG、RANKL的mRNA的表达情况,以β-actin作为内参对照。
④Von Kossa矿化结节
将MC3T3-E1细胞接种于6孔细胞培养板中,每孔1ml细胞悬液。待细胞长成细胞单层后,弃去原培养液,加入不同浓度的Asp(5μM、10μM和20μM),每孔1ml。培养72h后,弃去原培养液,加入条件培养液(含有50μg/ml维生素C、10mMβ-甘油磷酸钠的DMEM细胞培养液),每孔3ml。继续培养17d,期间2~3d换液一次。弃去原培养液,用PBS洗两次,然后进行染色。在显微镜下观察矿化结节产生的情况并进行拍照。
2、实验结果:
①细胞增殖功能检测
CCK-8测定结果表明Asp可以剂量、时间依赖性地促进MC3T3-E1细胞增殖,与空白组相比有明显的统计学差异(图1,P<0.01或P<0.05)。Asp作用24h与空白组比较,各浓度均无明显的促增殖作用(图1,P>0.05);但是作用48h、72h后,Asp(5μM、10μM和20μM)对MC3T3-E1细胞有明显的促增殖作用(图1,P<0.01或P<0.05)。
②ALP活性检测
经条件培养7d后,再用不同浓度的Asp(5μM、10μM和20μM)作用于MC3T3-E1细胞24h、48h、72h,提取总蛋白检测ALP活性。实验结果表明:不同浓度Asp作用细胞24h后,ALP活性没有明显变化;作用48h后,与空白组比较,只有20μM的Asp可以显著增加ALP活性(图2,P<0.05);作用72h后,5μM、10μM和20μM的Asp可以剂量依赖性的增加ALP活性,与空白组比较有明显的统计学差异(图2,P<0.01或P<0.05)。
③OPG/RANKL mRNA表达的检测
MC3T3-E1细胞,经过Asp作用72h后,提取总RNA,通过Real time RT-PCR检测OPG和RANKL mRNA的表达情况,并计算OPG/RANKL的比值。实验结果表明:Asp(5μM、10μM和20μM)不仅可以剂量依赖性的下调RANKL mRNA的表达水平(图3b,P<0.01或P<0.05),同时还能够剂量依赖性的上调OPG mRNA的表达水平(图3a,P<0.01或P<0.05)。与空白相比较,10μM和20μM的Asp可以显著地增加OPG/RANKL的比值(图3c,P<0.01)。
④Asp对MC3T3-E1细胞矿化情况的影响
Von Kossa染色后,可以在镜下观察到黑色的矿化结节(图4)。MC3T3-E1细胞经过Asp处理后,矿化结节的数量及面积与空白组相比都有增加的趋势,与对照组相比10μM和20μM的Asp可以显著地促进矿化结节的产生。表明:10μM和20μM的Asp能够促进钙盐的沉积,使MC3T3-E1细胞的矿化能力增强,从而使矿化结节产生的数量及面积增加。
综上所述,车叶草苷可以促进MC3T3-E1细胞增殖与分化,使ALP活性增高,上调OPG/RANKL的比值,促进骨的形成以及矿化结节的生成。
对于任何熟悉本领域的技术人员而言,在不脱离本发明技术方案范围情况下,都可利用上述揭示的技术内容对本发明技术方案作出许多可能的变动和修饰,或修改为等同变化的等效实施例。因此,凡是未脱离本发明技术方案的内容,依据本发明的技术实质对以上实施例所做的任何简单修改、等同变化及修饰,均应仍属于本发明技术方案保护的范围内。
Claims (9)
1.车叶草苷在制备成骨细胞系MC3T3-E1增殖与分化药物中的应用。
2.根据权利要求1所述的应用,其特征在于,所述药物为治疗或预防骨质疏松的药物。
3.车叶草苷在制备预防骨质疏松保健食品中的应用。
4.根据权利要求1~3任一项所述的应用,其特征在于,所述车叶草苷的浓度为5~20μM。
5.根据权利要求4所述的应用,其特征在于,所述车叶草苷的浓度为10~20μM。
6.一种预防或治疗骨质疏松的药物组合物,其特征在于,所述药物组合物以车叶草苷为活性成分。
7.根据权利要求6所述的药物组合物,其特征在于,所述药物组合物以车叶草苷为唯一活性成分。
8.根据权利要求6所述的药物组合物,其特征在于,所述药物为口服制剂或注射制剂。
9.一种预防骨质疏松的保健食品,其特征在于,所述保健食品包含车叶草苷。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310243299.2A CN116098913A (zh) | 2023-03-14 | 2023-03-14 | 车叶草苷在成骨细胞系mc3t3-e1增殖与分化的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310243299.2A CN116098913A (zh) | 2023-03-14 | 2023-03-14 | 车叶草苷在成骨细胞系mc3t3-e1增殖与分化的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116098913A true CN116098913A (zh) | 2023-05-12 |
Family
ID=86254481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310243299.2A Pending CN116098913A (zh) | 2023-03-14 | 2023-03-14 | 车叶草苷在成骨细胞系mc3t3-e1增殖与分化的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116098913A (zh) |
-
2023
- 2023-03-14 CN CN202310243299.2A patent/CN116098913A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fan et al. | Myricetin ameliorates glucocorticoid-induced osteoporosis through the ERK signaling pathway | |
Jin et al. | Sclareol prevents ovariectomy-induced bone loss in vivo and inhibits osteoclastogenesis in vitro via suppressing NF-κB and MAPK/ERK signaling pathways | |
Zhang et al. | Metformin protects chondrocytes against IL-1β induced injury by regulation of the AMPK/NF-κ B signaling pathway | |
Liu et al. | Chondrocyte-derived exosomes promote cartilage calcification in temporomandibular joint osteoarthritis | |
Xu et al. | Small molecule natural compound targets the NF‐κB signaling and ameliorates the development of osteoarthritis | |
KR20160015113A (ko) | 골다공증 예방 및 치료용 조성물 | |
Han et al. | Corosolic acid protects rat chondrocytes against IL-1β-induced ECM degradation by activating autophagy via PI3K/AKT/mTOR pathway and ameliorates rat osteoarthritis | |
CN110934858A (zh) | 巴西木素作为α-突触核蛋白聚集抑制剂在制备药物、保健品或食品中的用途 | |
CN116098913A (zh) | 车叶草苷在成骨细胞系mc3t3-e1增殖与分化的应用 | |
CA2471232A1 (en) | Calcium l-threonate for preventing or treating bone fracture | |
WO2023137985A1 (zh) | 一种调节骨骼肌糖代谢与线粒体生成的膳食营养补充剂及其应用 | |
CN1857713A (zh) | 一种治疗骨质疏松症的药物 | |
CN103933060B (zh) | 红芪多糖在制备预防或治疗骨质疏松药物或保健品中的应用 | |
CN109806256A (zh) | 乔松素在制备用于治疗肺纤维化疾病药物中的应用 | |
CN109432075A (zh) | 间羟基苯丙酸在制备抗骨质疏松症药物中的应用 | |
KR20170036928A (ko) | IKKε 억제제를 유효성분으로 함유하는 만성 부비동염 예방 또는 치료용 약학조성물 | |
CN113648306A (zh) | 佛手柑素在预防或治疗骨质疏松和/或骨丢失中的应用 | |
KR100416842B1 (ko) | 하르파지드관련 화합물을 유효성분으로 함유하는 골다공증 예방과 치료용 약학적 조성물 | |
CN106389432B (zh) | 氯化两面针碱在制备抗骨质疏松和骨丢失疾病中的应用 | |
CN112716928A (zh) | 辣椒素在抑制nlrp3炎症小体活化中的应用 | |
CN111870689A (zh) | 一种纳豆激酶在治疗骨质疏松药物中的应用 | |
WO2015053726A2 (en) | Anti-obesity product | |
CN109806255A (zh) | 香叶木素在制备用于治疗肺纤维化疾病药物中的应用 | |
CN113616792B (zh) | 提高smurf1蛋白表达量的试剂在制备防治钙化性主动脉瓣疾病的药物中的应用 | |
CN109674784A (zh) | 升麻素在制备用于治疗肺纤维化疾病的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |